Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Cancer researchers have discovered that a notorious oncogene may occasionally wind up exposed on the outside of tumor cells, hinting at a surprising new immunotherapy target.
Meanwhile, Trump continues to win the messaging war on drug pricing, and biotech’s social circles get awkward again with an Epstein-linked investor’s return.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
